Drug intelligence / Profile preview

NV-623

Development stage: Preclinical
Lead developer: Integrated Biosciences
Modality: Small Molecules
Administration: Topical

Overview

NV-623 is an investigational small molecule discovered using an artificial intelligence-guided drug discovery platform by Re:You, in collaboration with Integrated Biosciences and LK Innovations. It is designed to promote hair follicle rejuvenation and treat hair loss conditions such as androgenetic alopecia. Mechanistically, NV-623 acts as a dermal papilla cell (DPC) potentiator, enhancing DPC viability, proliferation, and metabolic activity. In preclinical studies, NV-623 demonstrated superior efficacy compared to minoxidil in stimulating DPC growth and increasing hair follicle organoid sprouting length. NV-623 is formulated alongside NV-624 and NV-273 in RE:YOU's topical NOVOGRO™-powered serum, which is currently being evaluated in a randomized, double-blind clinical trial.

Other names: NOVOGRO-623NOVOGRO623NOVOGRO 623NOVOGRO™-623

Beyond the preview

Go deeper on NV-623.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NV-623.